Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment

Published:2020-12 Issue:12 Volume:15 Page:1857-1870
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Duan Jianchun,Xu JiaChen,Wang Zhijie,Bai Hua,Cheng Ying,An Tongtong,Gao Hongjun,Wang Kai,Zhou Qing,Hu Yanping,Song Yong,Ding Cuimin,Peng Feng,Liang Li,Hu Yi,Huang Cheng,Zhou Caicun,Shi Yuankai,Han Jiefei,Wang Di,Tian Yanhua,Yang Zhenlin,Zhang Li,Chuai Shaokun,Ye Junyi,Zhu Guanshan,Zhao Junhui,Wu Yi-long,Wang Jie

Funder

Bristol-Myers Squibb

Lilly

Pfizer

National Natural Sciences Foundation Key Program

Chinese Academy of Medical Sciences Innovation Fund

Aiyou Foundation

Ministry of Education Innovation

China National Natural Sciences Foundation

Beijing Natural Science Foundation

Beijing Novel Program

Central Research Institute Fund of Chinese Academy of Medical Sciences

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference40 articles.

1. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

2. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

3. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

4. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study;Wu;Ann Oncol,2015

5. Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China;Wu;Asia Pac J Clin Oncol,2012

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Germline potential should not be overlooked for cancer variants identified in tumour-only somatic mutation testing;Pathology;2024-06

2. Distinguishing EGFR mutation molecular subtypes based on MRI radiomics features of lung adenocarcinoma brain metastases;Clinical Neurology and Neurosurgery;2024-05

3. Identification of metabolism-related gene signature in lung adenocarcinoma;Medicine;2023-11-24

4. Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer;Scientific Reports;2023-11-13

5. ADAM12 promotes the resistance of lung adenocarcinoma cells to EGFR-TKI and regulates the immune microenvironment by activating PI3K/Akt/mTOR and RAS signaling pathways;International Immunopharmacology;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3